March 26, 2023

Republic21

TB Alliance committed to accessibility of TB therapy in India

3 min read
1 year ago dsprime

The DCGI (Drug Controller General of India) approved TB drug, pretomanid, for conditional access under the National Tuberculosis Elimination Program (NTEP), can play a significant role towards elimination of highly drug-resistant TB in India 

Pretomanid is a ‘made in India’ product used as part of a six-month treatment regimen with reported efficacy of 90%; has potential to contribute to India’s ‘TB Elimination program by 2025’ 

New Delhi, India March 24: The world continues to battle against pandemics, including COVID-19 and tuberculosis (TB). March 24, marks World TB Day and TB Alliance, a global not-for-profit organization, is joining with partners around the globe to raise awareness of one of the world’s oldest diseases. TB had been the world’s leading infectious killeruntil COVID-19. This new pandemic has shown that new tools, diagnostics, drugs, and vaccines can be quickly developed and deployed with the adequate funding and political will. The same resources are needed to bring the TB pandemic under control and make progress toward a TB-free world.

In July 2020, the Drug Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.

On the occasion of World TB Day, Sandeep Juneja, Sr. VP, Market Access at TB Alliance, said“New regimens are urgently needed to treat this deadly infectious disease, especially drug-resistant forms of TB which have a history of poor cure rates and treatments with often intolerable side effects. We welcome the fact that more than 30 countries, including India, have obtained pretomanid-based regimens to treat highly drug-resistant forms of TB.TB Alliancestands ready to work side by side and learn from India and every other country seeking to implementnew TB therapies. Our job is not done until each treatment we develop is accessible to every person who needs it.”

A government-led study of the regimen in India called *mBPaL commenced in October 2021 and is now enrolling patients at three sites out of a planned 11. It is scheduled to reach its primary completion in 2023 after enrolling 400 patients.

TB Alliance manages the largest portfolio of TB drug candidates, with more than 30 projects under active development. Its researchers and research partners are working to advance the development of new TB compounds and medicines, with a goal to develop a short, simple, and affordable TB regimens suitable for all people with TB.

To date, 17 countries or regulatory bodies, including India, have approved pretomanid as part of the BPaL regimen for the treatment of patients with highly drug-resistant forms of TB. Regulatory applications have been submitted to another 13 countries and counting by Viatris, TB Alliance’s global commercialization partner for pretomanid as part of the regimen. Viatris is joined by Macleods, Lupin, and Hongqi Pharma in holding licenses for pretomanid in countries with high TB burdens.

Data from TB Alliance’s ZeNix trial of the BPaL regimen, presented in 2021, demonstrated improvement in the safety and tolerability of the BPaL regimen with alterations in linezolid dosing with sustained favorable outcomes in 89 precent of all participants.

Though important advances have been made in recent years, the need to invest in TB research and development is even more apparent amidst the COVID-19 pandemic, which has already reversed hard-won progress against TB. In 2020, the world saw the first increase in TB deaths since 2005, and a 15 percent reduction in the number of people treated for drug-resistant TB.

Bringing the TB pandemic under control can only be realized through global commitment and collaboration. TB Alliance is committed to contributing to this aspiration by inventing novel therapies that radically reshape the treatment landscape and save lives.

*BPaL regimen combines the antibiotics bedaquiline (B), pretomanid (Pa) and linezolid (L)

dsprime

See author's posts

Tags:

More Stories

1 min read

BEVU BELLA UGADI (Ugadi Pachadi in Karnataka)

3 days ago dsprime
2 min read

Sree Metaliks’ SAANCHI Initiative Launches Mission to Improve Women’s Health and Expand Menstrual Hygiene Awareness in Odisha

5 days ago dsprime
1 min read 2

CR Patil and Rashmi Saboo promote the financial empowerment of 100 girls with Sukanya Samriddhi Yojana accounts

1 week ago dsprime

110 thoughts on “TB Alliance committed to accessibility of TB therapy in India”

  2. Wonderful blog! I found it while searching on Yahoo News. Do you have any
    tips on how to get listed in Yahoo News? I’ve been trying for a while but I never seem to get there!
    Appreciate it

  7. Hi there! I know this is kinda off topic but I was wondering if you knew where I could find a captcha plugin for my
    comment form? I’m using the same blog platform as yours and
    I’m having trouble finding one? Thanks a lot!

  8. fantastic put up, very informative. I ponder why the opposite experts of this
    sector don’t notice this. You should continue your writing.
    I’m confident, you’ve a great readers’ base already!

  11. If you are going for best contents like myself, simply pay
    a visit this site all the time because it gives feature contents, thanks

  12. Undeniably imagine that that you said. Your favorite justification appeared to be at
    the internet the simplest factor to consider of. I say to you, I certainly get annoyed even as other people consider issues that they
    plainly do not realize about. You controlled to hit the nail upon the top and
    outlined out the entire thing with no need side effect ,
    other people could take a signal. Will likely be back to get more.
    Thanks

  13. I have been browsing online more than 3 hours today, yet I never found any interesting article like yours.
    It’s pretty worth enough for me. In my view, if all site owners and bloggers made good content as you
    did, the web will be a lot more useful than ever before.

  22. Comprehensive side effect and adverse reaction information. Definitive journal of drugs and therapeutics.
    ivermectin cost
    Drugs information sheet. Actual trends of drug.

  39. Everything what you want to know about pills. All trends of medicament.
    https://nexium.top/# buy cheap nexium pill
    Definitive journal of drugs and therapeutics. Learn about the side effects, dosages, and interactions.

  45. All trends of medicament. Everything about medicine.
    https://nexium.top/# where can i get generic nexium without dr prescription
    Commonly Used Drugs Charts. What side effects can this medication cause?

  64. Comprehensive side effect and adverse reaction information. Some trends of drugs.
    buy ed pills
    drug information and news for professionals and consumers. Definitive journal of drugs and therapeutics.

  65. Some are medicines that help people when doctors prescribe. Get information now.
    ed pills otc
    Prescription Drug Information, Interactions & Side. Read information now.

  66. Prescription Drug Information, Interactions & Side. Drugs information sheet.
    [url=https://edonlinefast.com]best otc ed pills[/url]
    safe and effective drugs are available. Long-Term Effects.

  97. safe and effective drugs are available. Comprehensive side effect and adverse reaction information.
    tadalafil cialis
    Everything what you want to know about pills. Everything information about medication.

  107. Read now. Cautions.

    https://clomidc.fun/ where to buy clomid pill

    [url=https://clomidc.fun/]can i get cheap clomid no prescription[/url]
    Everything what you want to know about pills. Top 100 Searched Drugs.

  108. п»їMedicament prescribing information. Learn about the side effects, dosages, and interactions.

    cheap clomid now
    All trends of medicament. Definitive journal of drugs and therapeutics.

Leave a Reply

Your email address will not be published.

You may have missed

3 min read

Surat Biz Fest, the Biggest business festival, creates a buzz across Indian business community

2 hours ago dsprime
3 min read

ZEEL’s Mind Wars app reaches 111K downloads on Google Play Store!

1 day ago dsprime
4 min read

Rewards and Loyalty Gateway Benepik nears 100 Crore Revenues in FY 22-23

1 day ago dsprime
5 min read

Data Intelligence Firm, Near, to Debut on Nasdaq Under Ticker “NIR”

1 day ago dsprime